CITIUS ONCOLOGY Business Summary

Citius Oncology, Inc. (CTOR) is a commercial-stage biopharmaceutical company that generates revenue primarily through the direct sale and licensing of its flagship oncology asset, LYMPHIR™ (denileukin diftitox-cxdl). Launched in the U.S. in December 2025, LYMPHIR is a first-in-class engineered IL-2 diphtheria toxin fusion protein indicated for relapsed or refractory cutaneous T-cell lymphoma (CTCL). The company’s business model leverages a dual-track commercialization strategy: internal U.S. sales operations optimized by AI-driven analytics and international revenue streams derived from exclusive distribution agreements with partners such as Uniphar for the European Union and regional specialists in the Middle East and Turkey. Citius Oncology operates as a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (CTXR), focusing on the high-growth immunotherapy segment of the oncology market. Direct competitors include Kyowa Kirin (Poteligeo), Helsinn Group (Valchlor), Rocket Pharmaceuticals, and Aura Biosciences; Citius differentiates itself by offering a unique dual mechanism of action that targets both malignant T-cells and regulatory T-cells in an underserved $400 million CTCL market. The leadership team is anchored by Chairman and CEO Leonard Mazur and Executive Vice Chairman Myron Holubiak, both of whom co-founded Leonard-Meron Biosciences prior to its pivotal merger with Citius. Mazur brings over five decades of pharmaceutical experience, having previously founded Genesis Pharmaceuticals and served as COO of Triax Pharmaceuticals, while Holubiak is the former President of Roche Laboratories. The executive suite is further strengthened by Chief Medical Officer Dr. Myron S. Czuczman, a renowned oncologist and former Vice President of Global Clinical Research at Celgene, and CFO Jaime Bartushak, a co-founder of Leonard-Meron with extensive expertise in life sciences capital formation. Citius Oncology is a "controlled company" with Citius Pharmaceuticals holding approximately 75% of the voting power, supported by notable institutional investors such as Armistice Capital, The Vanguard Group, and Geode Capital Management. The Board of Directors includes seasoned industry veterans like Dennis McGrath and Suren Dutia, providing strategic oversight as the company scales its commercial infrastructure.